Skip to main content

Plaintiffs Claim Recalled Valsartan Pills Preserved Badly

Plaintiffs Claim Recalled Valsartan Pills Preserved Badly

Plaintiffs Claim Recalled Valsartan Pills Preserved Badly

Introduction

Attorneys representing plaintiffs in the federal valsartan litigation indicated that the drug makers have not preserved recalled pills properly, possibly spoiling or destroying important evidence about contaminated versions of the blood pressure drug.

On January 14, a letter was sent to U.S. Magistrate Judge Joel Schneider, stating that the recalled valsartan pills have been destroyed, and asking the court to intervene. The Plaintiffs attorneys are asking the court to issue an order reiterating the drug makers’ obligations to preserve evidence.

In response to the letter, the drug makers attorneys argued that the preservation requests by the plaintiffs are asking them to violate federal law, which has strict rules on the retrieval of recalled products and what should happen with the pills. The letter indicates that the plaintiffs want every manufacturer, wholesaler, and pharmacy to use significant resources to preserve and store every valsartan pill.

On January 16, Magistrate Judge Schneider issued a new order indicating several discovery problems but did not directly address the preservation of the pills. However, the order reiterates that any communications between defendants and the FDA regarding the pills and recalls within seven days of them being sent or received should be given to the plaintiffs. The issue is expected to be discussed in the next status conference scheduled for January 28.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!